Cloning Facility is a Russian biotechnology company that performs deoxyribonucleic acid synthesis, assembly of arbitrary genetic structures and creation of transgenic organisms to order.
In 2020, the range of services provided by the organization expanded to include custom research and development work for large industrial enterprises.
The main clients of Cloning Facility company are research laboratories and biotechnology companies. In the future, the company plans to expand its presence in the Russian market and also to enter the international market.
Cloning Facility company grew out of a non-profit project of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences, where the company's founders work, due to the fact that the founders faced the lack of companies offering fast assembly of genetic structures both in Russia and abroad.
At first, the project provided services to a small number of laboratories; however, the number of orders began to grow rather rapidly, including from other Russian research institutes. It was at this stage that the company founders decided to develop this project as an independent business.
Fast deoxyribonucleic acid assembly was made possible by the company's technological solutions aimed at automating both the design of genetic structures and the optimization of cloning methods. The technology used allows reducing the cost and time of deoxyribonucleic acid assembly by many times, transforming the market by outsourcing this task.
Cloning Facility produces two types of products - standardized biotechnology services (fast and cheap) and complex research (expensive).
Since the beginning of its activities in 2019, the flow of orders made by Cloning Facility is constantly growing. In addition to the existing services, the company Cloning Facility is developing new areas, which allow the company to provide growth in sales and demand for its products in the market.
Cloning Facility company actively cooperates with research laboratories of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and other research institutes in Russia and Europe, Russian start-ups, as well as with major biotechnological and biomedical enterprises.